In addition, we found the serum FABP4 and FABP6 levels could provide a potential biomarker to predict CRC, especially, combined detection of CEA with FABP4 and FABP6 could improve the diagnostic efficacy (sensitivity and specificity) of CRC. Here, CEACAM5 is linked to colorectal carcinoma.